Clinical Trial: A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma.

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593040) titled 'A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma.' on May 11.

Brief Summary: This study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and high risk clear cell renal cell carcinoma (ccRCC).

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Neoadjuvant/Adjuvant Renal Cell Carcinoma

Intervention: DRUG: ...